查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1378889

急性骨髓性白血病治療市場：2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測

Acute Myeloid Leukemia Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

概要

2022年，全球急性骨髓性白血病治療市場規模達到10.732億美元。展望未來， IMARC Group預計到2028年市場規模將達到21.991億美元，2022-2028年複合年成長率（CAGR）為12.7%。

急性骨髓性白血病（AML）是指導致異常細胞快速生長的克隆性惡性腫瘤。它主要影響骨髓和白血球 (WBC)，其特徵是皮膚變色、呼吸困難、疲勞、體溫高、體重減輕、牙齦出血和流鼻血。一些常用的 AML 療法包括化療、免疫、標靶和荷爾蒙療法以及外科手術。這些療法通常與幹細胞移植相結合，以提高療效、減少併發症並增強身體的免疫系統。

全球白血病盛行率不斷上升是推動市場成長的關鍵因素之一。此外，老年人口的增加也推動了市場的成長，老年人口更容易罹患此類疾病。 AML 主要是由影響血球生成水平的體內基因突變引起的。與此一致的是，聯合療法和標靶療法的廣泛採用以及對癌症治療可用替代方案的認知不斷提高也有利於市場成長。此外，改良的免疫毒素、烷化劑、單株抗體和多重抗藥性調節劑的出現是另一個主要的生長誘導因素。這些療法提供了長期的結果、更高的功效、對白血病細胞的早期和準確識別，並減少了癌症復發的機會。其他因素，包括腫瘤學領域的廣泛研究和開發（R&D）活動，以及現有醫療基礎設施的顯著改善，預計將進一步推動市場發展。

本報告回答的關鍵問題：

  • 迄今為止，全球急性骨髓性白血病治療市場表現如何，未來幾年將如何表現？
  • COVID-19 對全球急性骨髓性白血病治療市場有何影響？
  • 主要區域市場有哪些？
  • 根據治療類型的市場分類是怎樣的？
  • 根據藥物類型分類的市場是怎麼樣的？
  • 根據給藥途徑，市場的分化為何？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球急性髓性白血病治療市場的結構如何？誰是主要參與者？
  • 產業競爭程度如何？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球急性骨髓性白血病治療市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：按治療類型分類的市場區隔

  • 阿糖胞苷
    • 市場走向
    • 市場預測
  • 蒽環類藥物
    • 市場走向
    • 市場預測
  • 烷基化劑
    • 市場走向
    • 市場預測
  • 抗代謝藥
    • 市場走向
    • 市場預測
  • 酪胺酸激酶抑制劑
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：按藥物類型分類的市場細分

  • 小分子藥物
    • 市場走向
    • 市場預測
  • 生物製藥
    • 市場走向
    • 市場預測

第 8 章：按管理途徑分類的市場

  • 口服
    • 市場走向
    • 市場預測
  • 注射劑
    • 市場走向
    • 市場預測

第 9 章：按地區分類的市場區隔

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 按國家/地區分類的市場細分
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbvie Inc.
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Celgene
    • Roche Holding AG
    • Gilead Sciences Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112023A3129

Abstract

The global acute myeloid leukemia therapeutics market size reached US$ 1,073.2 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 2,199.1 Million by 2028, exhibiting a growth rate (CAGR) of 12.7% during 2022-2028.

Acute myeloid leukemia (AML) refers to a clonal malignancy leading to the rapid growth of abnormal cells. It primarily impacts the bone marrow and white blood cells (WBCs) and is characterized by the discoloration of skin, breathlessness, fatigue, high body temperatures, weight loss, bleeding gums and nosebleeds. Some of the commonly used AML therapies include chemo-, immuno-, targeted- and hormonal therapies and surgical procedures. These therapeutics are usually combined with stem cell transplants to increase the efficacy, minimize complications and strengthen the immune system of the body.

The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such disorders, is also driving the market growth. AML is primarily caused by genetic mutations in the body that impacts the levels of blood cell production. In line with this, the widespread adoption of combination and targeted therapies and increasing awareness regarding the available alternatives for cancer treatment are also favoring the market growth. Additionally, the advent of improved immunotoxins, alkylating agents, monoclonal antibodies and multidrug-resistant modulators is another major growth-inducing factor. These therapeutics offer prolonged results, higher efficacy, early and accurate identification of leukemia cells and reduced chances of cancer relapse. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with significant improvements in the existing healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global acute myeloid leukemia therapeutics market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on treatment type, drug type and route of administration.

Breakup by Treatment Type:

Cytarabine

Anthracycline Drugs

Alkylating Agents

Anti-Metabolites

Tyrosine Kinase Inhibitors

Others

Breakup by Drug Type:

Small Molecule Drugs

Biopharmaceuticals

Breakup by Route of Administration:

Oral

Injectables

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene, Roche Holding AG, Gilead Sciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report:

  • How has the global acute myeloid leukemia therapeutics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global acute myeloid leukemia therapeutics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global acute myeloid leukemia therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Acute Myeloid Leukemia Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Cytarabine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anthracycline Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alkylating Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Anti-Metabolites
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Tyrosine Kinase Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biopharmaceuticals
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectables
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbvie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Celgene
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Roche Holding AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Gilead Sciences Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Takeda Pharmaceutical Company Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Acute Myeloid Leukemia Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017-2022
  • Figure 3: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 4: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Treatment Type (in %), 2022
  • Figure 5: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Drug Type (in %), 2022
  • Figure 6: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Route of Administration (in %), 2022
  • Figure 7: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Acute Myeloid Leukemia Therapeutics (Cytarabine) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Acute Myeloid Leukemia Therapeutics (Cytarabine) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Acute Myeloid Leukemia Therapeutics (Anthracycline Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Acute Myeloid Leukemia Therapeutics (Anthracycline Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Acute Myeloid Leukemia Therapeutics (Alkylating Agents) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Acute Myeloid Leukemia Therapeutics (Alkylating Agents) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Acute Myeloid Leukemia Therapeutics (Anti-Metabolites) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Acute Myeloid Leukemia Therapeutics (Anti-Metabolites) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Acute Myeloid Leukemia Therapeutics (Tyrosine Kinase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Acute Myeloid Leukemia Therapeutics (Tyrosine Kinase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Acute Myeloid Leukemia Therapeutics (Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Acute Myeloid Leukemia Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Acute Myeloid Leukemia Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Acute Myeloid Leukemia Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Acute Myeloid Leukemia Therapeutics (Biopharmaceuticals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Acute Myeloid Leukemia Therapeutics (Biopharmaceuticals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Acute Myeloid Leukemia Therapeutics (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Acute Myeloid Leukemia Therapeutics (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Acute Myeloid Leukemia Therapeutics (Injectables) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Acute Myeloid Leukemia Therapeutics (Injectables) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: North America: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: North America: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: United States: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: United States: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Canada: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Canada: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Asia-Pacific: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Asia-Pacific: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: China: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: China: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Japan: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Japan: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: India: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: India: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: South Korea: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: South Korea: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Australia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Australia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Indonesia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Indonesia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Europe: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Europe: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Germany: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Germany: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: France: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: France: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: United Kingdom: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: United Kingdom: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Italy: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Italy: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Spain: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Spain: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Russia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Russia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Latin America: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Latin America: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Brazil: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Brazil: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Mexico: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Mexico: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market: Breakup by Country (in %), 2022
  • Figure 77: Global: Acute Myeloid Leukemia Therapeutics Industry: SWOT Analysis
  • Figure 78: Global: Acute Myeloid Leukemia Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Acute Myeloid Leukemia Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Acute Myeloid Leukemia Therapeutics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Treatment Type (in Million US$), 2023-2028
  • Table 3: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 4: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 5: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Acute Myeloid Leukemia Therapeutics Market: Competitive Structure
  • Table 7: Global: Acute Myeloid Leukemia Therapeutics Market: Key Players